TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06552169: REgulatory T Cell Therapy to Achieve Immunosuppression REduction

Sponsor: Singulera Therapeutics Inc. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 34 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,138,500

Rescue Site Savings

+$759,000

Unlock Full NCT06552169 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06552169 Rescue Dossier →